Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated ...

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug ...

Co announces that the FDA has granted final approval for the Company's Abbreviated New Drug Application for Rabeprazole Sodium Delayed-Release Tablets, 20 mg. TEVA's Rabeprazole Sodium Delayed-Release ...

March 13, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for rabeprazole sodium 20-mg delayed-release tablets and ranitidine HCl 15-mg/mL oral ...